IL284448A - Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors - Google Patents

Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Info

Publication number
IL284448A
IL284448A IL284448A IL28444821A IL284448A IL 284448 A IL284448 A IL 284448A IL 284448 A IL284448 A IL 284448A IL 28444821 A IL28444821 A IL 28444821A IL 284448 A IL284448 A IL 284448A
Authority
IL
Israel
Prior art keywords
hsv
immunity
herpes simplex
simplex virus
vaccine vectors
Prior art date
Application number
IL284448A
Other languages
Hebrew (he)
Other versions
IL284448B1 (en
IL284448B2 (en
Original Assignee
Albert Einstein College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/238,933 external-priority patent/US10918712B2/en
Application filed by Albert Einstein College Of Medicine filed Critical Albert Einstein College Of Medicine
Publication of IL284448A publication Critical patent/IL284448A/en
Publication of IL284448B1 publication Critical patent/IL284448B1/en
Publication of IL284448B2 publication Critical patent/IL284448B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL284448A 2019-01-03 2020-01-03 Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors IL284448B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/238,933 US10918712B2 (en) 2014-03-03 2019-01-03 Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
PCT/US2020/012170 WO2020142677A1 (en) 2019-01-03 2020-01-03 Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Publications (3)

Publication Number Publication Date
IL284448A true IL284448A (en) 2021-08-31
IL284448B1 IL284448B1 (en) 2023-08-01
IL284448B2 IL284448B2 (en) 2023-12-01

Family

ID=69400650

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284448A IL284448B2 (en) 2019-01-03 2020-01-03 Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Country Status (7)

Country Link
EP (1) EP3906052A1 (en)
JP (2) JP2022517322A (en)
CN (1) CN113727728A (en)
AU (1) AU2020204688A1 (en)
CA (1) CA3124523A1 (en)
IL (1) IL284448B2 (en)
WO (1) WO2020142677A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023245159A1 (en) * 2022-06-16 2023-12-21 Albert Einstein College Of Medicine Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110938604B (en) * 2014-03-03 2024-04-05 阿尔伯特爱因斯坦医学院 Recombinant herpes simplex virus 2 (HSV-2) vaccine vector
US10918712B2 (en) * 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
DE102014117280A1 (en) * 2014-11-25 2016-05-25 Pilz Gmbh & Co. Kg Safety switching device for switching on and off safely an electrical consumer

Also Published As

Publication number Publication date
CA3124523A1 (en) 2020-07-09
CN113727728A (en) 2021-11-30
AU2020204688A1 (en) 2021-07-15
IL284448B1 (en) 2023-08-01
EP3906052A1 (en) 2021-11-10
KR20210112343A (en) 2021-09-14
JP2024016032A (en) 2024-02-06
IL284448B2 (en) 2023-12-01
WO2020142677A1 (en) 2020-07-09
JP2022517322A (en) 2022-03-08

Similar Documents

Publication Publication Date Title
GB202108457D0 (en) Recombinant varicella-zoster virus vaccine
EP3113801A4 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
MA49463A (en) HERPES SIMPLEX VACCINE
ZA202101615B (en) African swine fever virus vaccine
IL282885A (en) Aav viral vectors and uses thereof
IL284448A (en) Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
SG11201803365RA (en) Herpes simplex virus vaccine
PH12019501067A1 (en) Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
WO2012158552A3 (en) 2'-fluoro-6'-methylene carbocyclic nuceosides and methods of treating viral infections
IL283344A (en) Recombinant viral vectors and nucleic acids for producing the same
IL287606A (en) Methods for treatment of subjects with preexisting immunity to viral transfer vectors
EA201790717A1 (en) METHODS AND COMPOSITIONS FOR THE INDUCTION OF PROTECTIVE IMMUNITY AGAINST INFECTION BY THE HUMAN IMMUNODEFICIENCY VIRUS
WO2016092460A3 (en) Cytomegalovirus antigens
IL286464A (en) Recombinant adeno-associated virus vectors
ZA202006656B (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
SG11202009452WA (en) Antibody-evading virus vectors
ZA202206789B (en) Varicella-zoster virus vaccine and application thereof
MX2022003590A (en) Vaccine in the form of a recombinant sero type 9 avian adenovirus vector.
MX2019010143A (en) Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection.
MX2020003591A (en) Recombinant non-pathogenic marek's disease virus constructs encoding multiple heterologous antigens.
EP3743084A4 (en) Recombinant viral vaccines
SG11202111515TA (en) Ebv-specific immune cells
MX2020002810A (en) Human cytomegalovirus immunogenic composition.
EP3600403A4 (en) Herpes simplex virus type-1(hsv-1) vaccine strain vc2 generating an anti-ehv-1 immune response
IL286415A (en) Monoclonal antibodies for prevention and treatment of herpes simplex viral infections